SOURCE: Levi & Korsinsky, LLP
NEW YORK, NY--(Marketwire - Sep 19, 2012) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Massachusetts on behalf of investors who acquired Vertex Pharmaceuticals Incorporated ("Vertex" or the "Company") (NASDAQ: VRTX) securities between May 7, 2012 and June 27, 2012.
For more information, click here: http://zlk.9nl.com/vertex-pharmaceuticals-vertex. There is no cost or obligation to you.
On May 7, 2012, Vertex issued a press release claiming that patients who received two of its drugs during clinical trials showed significant improvement in their lung functions. Between May 7, 2012 and May 25, 2012, certain Vertex officers and directors sold over $22 million of their personally owned shares. Then, on May 29, 2012, Vertex issued a series of press releases in which it acknowledged that the results from its clinical trials were not as positive as previously indicated. These results were further restated on June 28, 2012. Upon this news, Vertex stock fell from a close of $61.11 on June 27, 2012, to a close of $51.18 on June 28, 2012.
If you suffered a loss in Vertex you have until November 5, 2012 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at firstname.lastname@example.org or by telephone at (877) 363-5972, or visit http://zlk.9nl.com/vertex-pharmaceuticals-vertex.
Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.